Evaluation of the effects of a standardized aqueous extract of Phyllanthus emblica fruits on endothelial dysfunction, oxidative stress, systemic inflammation and lipid profile in subjects with metabolic syndrome: a randomised, double blind, placebo controlled clinical study

Pingali Usharani* , Padma Latha Merugu and Chandrasekhar Nutalapati

Abstract

Background: Endothelial dysfunction (ED) has been observed in individuals with metabolic syndrome (MetS) and contributes to the initiation and progression of atherosclerosis. The primary management of MetS involves lifestyle modifications and treatment of its individual components with drugs all of which have side effects. Thus, it would be of advantageous if natural products would be used as adjuncts or substitutes for conventional drugs. The aim of the present study was to evaluate the effect of standardized aqueous extract of fruits of Phyllanthus emblica (P. emblica) 250 mg and 500 mg twice daily on ED, oxidative stress, systemic inflammation and lipid profile in subjects with MetS.

Methods: In this randomised, double-blind, placebo-controlled clinical study endothelial function was measured by calculating reflection index (RI) using digital plethysmograph. Oxidative stress biomarkers used were nitric oxide (NO), glutathione (GSH) and malondialdehyde (MDA). Systemic inflammation was measured by determining high sensitivity C-reactive protein (hsCRP) and dyslipidemia by lipid profile. ANOVA, paired and unpaired t-test were used. P-value < 0.05 was considered statistically significant.

Results: Out of 65 screened subjects all 59 enrolled completed the study. P. emblica aqueous extract (PEE), 250 mg and 500 mg twice daily dosing, showed significant reduction in mean RI, measure of endothelial function, at 8 and 12 weeks (p < 0.001) compared to baseline and placebo. Significant mean % change was seen in oxidative stress biomarkers, NO (+ 41.89%, + 50.7%), GSH (+ 24.31%, + 53.22%) and MDA (− 21.02%, − 31.44%), and systemic inflammation biomarker, hsCRP (− 39.68%, − 53.77%) (p < 0.001) at 12 weeks with 250 mg and 500 mg twice daily dosage respectively. Significant mean % change was also seen at 12 weeks with TC (− 7.71%, − 11.11%), HDL-C (+ 7.33% + 22.16%, p < 0.05), LDL-C (− 11.39%, − 21.8%) and TG (− 9.81%, − 19.22%) respectively with 250 mg and 500 mg twice daily (p < 0.001). PEE 500 mg twice daily was significantly more efficacious than the 250 mg twice daily and placebo. No participant discontinued the study because of adverse events.

(Continued on next page)
Background

Metabolic syndrome (MetS) is characterized by the coexistence of multiple interrelated cardiovascular (CV) risk factors in a single individual [1]. The National Cholesterol Education Program’s Adult Treatment Panel III (ATP III) identified six components of the MetS: abdominal obesity, insulin resistance with or without glucose intolerance, atherogenic dyslipidaemia, raised blood pressure, prothrombotic state, and proinflammatory state [2]. MetS affects 25% of the world population, and its incidence is gradually increasing [3].

Endothelial dysfunction (ED) is abnormal functioning of the endothelial cells, caused by a decrease in bioavailability of vasodilator substances, particularly nitric oxide (NO), and increase of vasoconstrictor substances. Numerous metabolic abnormalities found in MetS result in endothelial cell dysfunction by affecting NO synthesis or degradation. The frequent metabolic abnormalities that may contribute to ED in patients with MetS are hyperinsulinaemia, hyperglycaemia, increase in the levels of fatty acids, C-reactive protein, oxidative stress, triglycerides and low-density lipoprotein cholesterol (LDL-C), and a decrease in high-density lipoprotein cholesterol (HDL-C) [4].

Both obesity and MetS have been independently associated with increased oxidative and inflammatory stress [5]. Oxidative stress is due to the production of reactive oxygen species (ROS), increased lipid peroxidation and impairment of antioxidant enzymatic defences, such as superoxide dismutase (SOD) or glutathione peroxidase (GPx) or combination of these factors [6]. Lipid peroxidation leads to the formation of malondialdehyde (MDA), and increased levels of MDA are found in obesity and insulin resistance. MDA can induce the increased expression of pro-inflammatory cytokines, resulting in systemic stress [7]. C-reactive protein (CRP) is a marker of systemic inflammation and a predictor of future atherosclerotic events [5]. Specifically, high sensitivity C-reactive protein (hsCRP) is an independent predictor of coronary heart disease [8].

Endothelial dysfunction (ED) is the earliest detectable functional disturbance in the natural history of the disease and a powerful predictor of future CV events [9]. Therapeutic interventions aimed at reducing CV risk factors may improve the endothelial function [10]. The primary management of MetS involves lifestyle modifications and treatment of its individual components, which includes lipid-lowering drugs, angiotensin-converting enzyme inhibitors, antidiabetic drugs, antiplatelet and antioxidant agents. However, the currently available pharmacologic interventions sometimes may not sufficiently improve endothelial function or may have side effects [11]. So, alternative treatments are needed to prevent the development of cardiovascular diseases (CVD) in subjects with MetS.

Phyllanthus emblica (Emblica officinalis, Amla) fruits are an important dietary source of polyphenolic compounds, which are low molecular weight hydrolysable tannins. This fruit extract has been reported to exhibit hypolipidemic, antidiabetic, anti-inflammatory, and antioxidant properties [12]. It has been reported that the tannoid principles of aqueous extract of Amla are a potent inhibitor of lipid peroxide generation and a scavenger of hydroxyl and superoxide radicals in vitro and in vivo [13].

Clinical studies provide evidence that Phyllanthus emblica extract has significantly improved endothelial function and reduced biomarkers of oxidative stress and systemic inflammation in patients with type 2 diabetes mellitus (T2DM) [14, 15]. As there is a paucity of data on the effect of Phyllanthus emblica on ED in MetS, the present study was undertaken to evaluate the effect of a standardized aqueous extract of Phyllanthus emblica, at 250 mg (PEE250) and 500 mg (PEE500) versus placebo twice daily on ED, oxidative stress, systemic inflammation and lipid profile in MetS.

Methods

The present study was prospective, randomised, double-blind and placebo-controlled with a 12-week duration, conducted in the Department of Clinical Pharmacology and Therapeutics, NIMS, Hyderabad,
India, after written approval from the Institutional Ethics Committee. Written informed consent was taken from all the subjects prior to participation in the study.

Subjects included in the study were of either gender, aged 30–68 years, having ED defined as ≤6% change in reflection index (RI) on post salbutamol challenge test and having MetS according to “The International Diabetes Federation” guidelines, dated 2006 [3]. Exclusion criteria consisted of subjects with severe uncontrolled hypertension, uncontrolled hyperglycemia, impaired hepatic or renal function, cardiac arrhythmia, chronic obstructive pulmonary disease (COPD), bronchial asthma, history of smoking, chronic alcoholism, malignancy or stroke, and any other serious disease requiring active treatment and treatment with any other herbal supplements. A total of 65 subjects were screened and 59 eligible subjects were randomised by computer generated block randomisation.

Study medications: The test products, PEE250 (CAPROS® 250) and PEE500 (CAPROS® 500) and matching placebo capsules used in the present study were supplied by Natreon Inc., USA. Each capsule of the PEE250 and PEE500 comprised of aqueous extract of the edible fruits of *P. emblica*, standardized by high performance liquid chromatography (HPLC) to contain not less than 60% of low molecular weight hydrolysable tannins (LMwHTs), comprising of Emblicanin–A, Emblicanin-B, Pedunculagin and Punigluconin as bioactives. Placebo capsules contained microcrystalline cellulose, lactose and magnesium stearate as excipients. The HPLC chromatogram of CAPROS® is shown in Fig. 1. The HPLC method used was the company’s In-house Monograph method. Briefly, 50 mg of *Pemblica* extract was dissolved in 50 ml of distilled water, and filtered through 0.22 μm syringe filter. The filtered solution (20 μL) was injected into Waters HPLC system (equipped with e2695 separation module, Photodiode Array detector (2998), and Empower3 pro Software). Compounds were separated on a NovaPak RP C18 150 × 3.9 mm, 4 μ (Waters corporation, WAT086344), column using 0.1 M sodium acetate–acetic acid buffer (pH 3.9) as the mobile phase at the flow rate of 0.6 ml/min and detection wavelength 280 nm. The percentage content of the LMwHTs was calculated using area of the LMwHTs peaks and the linear regression equation of the external standard.

Eligible subjects were enrolled and randomised by the investigator. The containers containing drugs were sequentially numbered and were dispensed by the pharmacist to the subjects according to the randomly allocated sequence so as to receive one capsule of PEE250, PEE500 or placebo twice daily for 12 weeks. Subjects returned for follow up visits at 4, 8 and 12 weeks of therapy, when subjects were evaluated for efficacy and safety. Pharmacodynamic evaluation of endothelial function (RI) was conducted at every visit. A 10 ml blood sample was collected in plain blood collection tubes after an overnight fast of 12 h for evaluation of NO, MDA, glutathione (GSH), hsCRP and lipid profile at baseline and at the end of 12 weeks of treatment. A complete physical examination and safety lab investigations for hematological, hepatic and renal biochemical parameters were conducted at baseline and at the end of the study, and as required during the study. Subjects were enquired for the presence of adverse drug reaction (ADR) at every visit, and any reported ADRs were recorded in the case report form. Compliance with therapy was assessed by pill count method.

Endothelial function was evaluated by salbutamol challenge test using the digital volume plethysmography.
(DPG) as reported by Chowienczyk et al. and Naidu et al. [16, 17]. Subjects were examined in supine position after 5 min of rest. A digital volume pulse (DVP) was obtained using photo plethysmograph (Pulse Trace PCA2, PT200, Micro Medical, Kent, UK) transmitting infra-red light at 940 nm, placed on the index finger of right hand. The signal from the plethysmograph was digitized using a 12 bit analogue to digital converter with a sampling frequency of 100 Hz. DVP waveforms were recorded over 20 s period and the height of the late systolic / early diastolic portion of the DVP was expressed as a percentage of the amplitude of the DVP to yield the RI, as per the procedure described in detail by Millasseau et al. [18]. After DVP recordings had been taken, three measurements of RI were calculated and the mean value was determined. Subjects were then administered 400 μg of salbutamol by inhalation. After 15 min, three measurements of RI were obtained again and the difference in mean RI before and after administration of salbutamol was used for assessing endothelial function. A change of ≤6% in RI post salbutamol was considered as endothelial dysfunction.

A spectrophotometer was used to estimate serum MDA (Thiobarbituric acid reactive substance test), NO (Colorimetric detection with Griess reagents) and GSH (Ellman’s method) levels [19–21].

Peripheral venous blood was collected in plain blood collection tubes after an overnight fast of 12 h after the last dose of medication for the estimation of haemoglobin, blood urea, serum creatinine, liver function test, lipid profile using standard techniques.

Primary and secondary efficacy parameters

The primary efficacy criterion was more than 6% change in RI (a measure of ED), assessed at 4.8 and 12 weeks. Secondary efficacy parameters included improvements in oxidative stress markers - NO, GSH and MDA, systemic inflammation marker hsCRP and the lipid profile at 12 weeks. Safety and tolerability assessment of the test medications were also conducted at 12 weeks.

Statistical analysis

Sample size calculation

Sample size calculation was done based on a previous study by Nishat Fatima et al. [14]. A sample size of 65 was estimated to recruit 59 patients considering a difference of 0.91% change in mean reflection index between PEE250 versus PEE500, with anticipated standard deviation of 0.92 at 5% level of significance and 80% power of study with screen failure rate of 10% and dropout rate of 15%.

Data were expressed as mean ± SD. The Kolmogorov-Smirnov test was used to assess the normality of the data. Unpaired t-test was performed to determine the statistical significance between groups and paired t-test was used to analyse within the group. One-way ANOVA was done for between groups analysis for absolute and mean percentage change. Posthoc analysis was done by Tukey’s test. A p-value of less than 0.05 was considered to be statistically significant. All statistical analysis was performed using the GraphPad Prism version 4.

Results

Out of the 65 screened subjects, 59 eligible subjects were randomised and all completed the study. Of the 59 subjects, 18 subjects received placebo, 20 subjects received PEE250 and 21 subjects received PEE500 twice daily. The subjects’ baseline characteristics are shown in Table 1, which indicate the study population was homogenous. Lipid abnormalities were present in all subjects.

The RI was used to assess endothelial function. It can be seen from Table 2, that baseline RI was nonsignificant between the three treatments. Treatment with PEE250 and PEE500 twice daily showed a significant reduction in mean RI at 8 and 12 weeks, indicating an improvement in endothelial function (p < 0.001). On further analysis, it was found that change in mean RI with PEE500 was significantly better compared to PEE250 (p < 0.05). Compared to placebo absolute change of RI was statistically significant with the two active treatments after 8 and 12 weeks of treatment.

The mean percent change in biomarker values was analysed for each of the study treatments at 12 weeks. Significant mean % change was seen in oxidative stress biomarkers, NO (+ 41.89%, + 50.7%), GSH (+ 24.31%, + 53.22%) and MDA (− 21.02%, − 31.44%), and the systemic inflammation biomarker, hsCRP (− 39.68%, − 53.77%) (p < 0.001) at 12 weeks with the 250 mg and 500 mg twice daily dosage respectively (Table 3), evidence of improved endothelial function and decreased systemic inflammation. PEE500 was significantly (p < 0.01 to p < 0.001) more efficacious than PEE250.

Significant mean % changes were also seen at 12 weeks with TC (− 7.71%, − 11.11%), HDL-C (+ 7.33%, p < 0.05, + 22.16%), LDL-C (− 11.39%, − 21.8%) and TG (− 9.81%, − 19.22%) respectively with PEE250 and PEE500 twice daily dosing (p < 0.001) (Table 4). Compared to PEE250 twice daily, treatment with PEE500 twice daily was more efficacious in improving TC (p < 0.05), LDL-C (p < 0.001), HDL-C (p < 0.001) and TG (p < 0.01) levels (Table 4).

There were no significant changes in mean heart rate, haematological, renal and hepatic functions with all treatments. All subjects tolerated therapy well. There were no serious adverse events recorded in the study. Two subjects each in the PEE250 and PEE500 groups complained of dyspepsia, and mild diarrhoea was noted in three subjects of the placebo group. All ADRs
resolved with symptomatic treatment. None of the patients discontinued the study prematurely because of these adverse events.

**Discussion**

In our study on 59 subjects the aqueous extract of *P. emblica* has shown statistically significant improvement in endothelial function, biomarkers of oxidative stress (NO, GSH, MDA), inflammatory marker (hsCRP) and lipid profile.

Studies by Hyun Young Kim et al. [22] and Manoj Gupta et al. [23] showed beneficial effects of *P. emblica* on parameters of MetS like oxidative stress biomarkers, lipid profile, and inflammatory markers. However, these studies did not evaluate endothelial function. In our study, RI was measured to assess endothelial function, using salbutamol challenge test employing DPG. Salbutamol challenge test used to assess endothelial function (RI) is a simple, non-invasive, reproducible and a reliable method [17]. This test does not require trained personnel unlike flow-mediated vasodilation (FMD) which requires sophisticated instrument, a skilled operator and has a chance for large inter-individual variability in the assessment of ED [17, 24]. In our earlier study using salbutamol challenge test, we have reported a significant reduction in mean RI with *P. emblica* 250 mg (from −2.25 ± 1.37 to −9.13 ± 2.56) and 500 mg (from −2.11 ± 0.98 to −10.04 ± 0.92) after 12 weeks of treatment in patients with T2DM [14]. In another study, we demonstrated a significant reduction in the mean RI compared to baseline and placebo with *Terminalia chebula* 250 mg [from −2.25 ± 0.70 to −3.72 ± 1.35 mg] and 500 mg [from −2.35 ± 0.85 to −6.14 ± 1.01] in MetS subjects [25]. Keisuke Fujitaka et al. in their study reported that administration of modified resveratrol (Longevinex) for 3 months improves endothelial function (measured using flow-mediated dilatation) in adults with MetS receiving standard treatment for T2DM, dyslipidaemia, or hypertension [26]. Results of the earlier mentioned study [14] are in accordance with our study where we found that treatment with a standardized aqueous extract of the edible fruits of *P. emblica* showed a significant reduction in mean RI compared to baseline and placebo using DPG method.

### Table 1 Baseline characteristics of subjects receiving Placebo, *Phyllanthus emblica* 250 mg and *Phyllanthus emblica* 500 mg

| Parameter | Placebo (A) (n = 18) | *Phyllanthus emblica* 250 mg (B) (n = 20) | *Phyllanthus emblica* 500 mg (C) (n = 21) |
|-----------|----------------------|------------------------------------------|------------------------------------------|
| Age in Yrs. | 56.89 ± 7.39 | 57.45 ± 7.44 | 57.24 ± 8.94 |
| Gender (M/F) | 14/4 | 14/6 | 15/6 |
| Bodyweight (Kg) | 78.17 ± 5.94 | 78.9 ± 6.61 | 78.9 ± 4.87 |
| Height (cm) | 161.17 ± 2.77 | 162.20 ± 3.53 | 162.14 ± 2.83 |
| BMI (Kg/m²) | 30.11 ± 1.72 | 30.02 ± 1.66 | 30.05 ± 1.70 |
| BMI (Kg/m²) < 30 | 5 (28%) | 7 (35%) | 6 (29%) |
| > 30 | 13 (72%) | 13 (65%) | 15 (71%) |
| SBP (mmHg) < 130 | 5 (28%) | 7 (35%) | 9 (43%) |
| > 130 | 13 (72%) | 13 (65%) | 12 (57%) |
| DBP (mmHg) < 85 | 10 (56%) | 12 (60%) | 8 (38%) |
| > 85 | 8 (44%) | 8 (40%) | 13 (62%) |
| FPG (mg/dL) < 100 | 13 (72%) | 11 (55%) | 8 (38%) |
| > 100 | 5 (28%) | 9 (45%) | 13 (62%) |

Values expressed as mean ± SD

### Table 2 Effect of Placebo, *Phyllanthus emblica* 250 mg and *Phyllanthus emblica* 500 mg on reflection index % (marker of endothelial function)

| Parameter | Placebo (A) (n = 18) | *Phyllanthus emblica* 250 mg (B) (n = 20) | *Phyllanthus emblica* 500 mg (C) (n = 21) |
|-----------|----------------------|------------------------------------------|------------------------------------------|
| RI (%) Baseline | After treatment | After treatment | Baseline | After treatment |
| 4 weeks | 8 weeks | 12 weeks | 4 weeks | 8 weeks | 12 weeks | 4 weeks | 8 weeks | 12 weeks |
| Mean ± SD | −2.27 ± 1.22 | −1.88 ± 1.24 | −1.46 ± 1.61 | −0.97 ± 2.45 | −0.97 ± 1.16 | −2.39 ± 0.87** | 1.54** | −2.52 ± 1.13 | −2.76 ± 0.99 | −4.86 ± 0.88*** | 1.58*** |
| p | NS | NS | NS | NS | < 0.001 | < 0.001 | NS | < 0.001 | < 0.001 |

Values expressed as mean ± SD

*SD standard deviation, RI Reflection index

*p < 0.001: compared to baseline value.  †p < 0.001: compared to placebo (A vs B, A vs C),  ‡p < 0.05: B vs C*
Increased oxidative stress plays a pivotal role in the pathogenesis of ED. Tung-Sheng Chen et al., have reported that oral administration of a 1:1 mixture of epigallocatechin gallate (EGCG) and *Emblica officinalis* extract 300 mg/day for 3 months significantly reduced the MDA (*p* < 0.001) levels in diabetic uremic patients [27]. Hyun Young Kim et al. demonstrated that oral administration of an ethyl acetate (EtOAc) extract of amla, to high-fructose diet fed rats at the dose of 20 mg/kg reduced the serum and hepatic mitochondrial MDA levels (*p* < 0.001) [22]. Our study had shown results similar to Tung-Sheng Chen et al. We found that 12 week therapy with PEE250 and PEE500 significantly decreased MDA levels compared to baseline and placebo. Additionally, we also evaluated NO and GSH and reported a statistically significant increase in their levels. In an earlier study done by us with *P. emblica* fruit powder, either 2 or 3 g per day for 21 days, significantly increased HDL-C (*p* < 0.05) and lowered TC (*p* < 0.05) and TG (*p* < 0.05), LDL-C (*p* < 0.05) levels in normal and diabetic human subjects [28]. Savita Khanna et al. demonstrated that 3 months oral supplementation of standardized extract of *P. emblica* fruit 500 mg twice daily, showed a significant decrease in LDL-C (*p* = 0.023) and total cholesterol/HDL ratio (*p* = 0.006) in overweight/Class-1 obese adults [8]. A pilot study done by Biswas et al. in human volunteers with a long smoking history, demonstrated a marginal decrease in cholesterol (–6.1%), triglyceride (–3.2%) and LDL (–9.4%) but a significant increase in serum HDL level (25.6%) with *Emblica officinalis* extract [29], the same extract used in the present study. Our results were in accordance with the reported study [29] and we also found that 12 weeks of treatment with PEE250 and PEE500 twice daily showed a significant change in TC (–7.71% and –11.11%), LDL-C (–11.39% and –21.8%), and TG (–9.81% and –19.22%) and HDL-C (+7.33% and +22.16%) compared to baseline for PEE250 and PEE500 respectively. PEE500 was significantly more efficacious than PEE250, while the placebo group had no significant effect on any of the parameters. The improvement in lipid parameters which were found in our study may be attributed to the fact that hypercholesterolemia induces a number of changes in vascular homeostasis and it appears that cholesterol-induced ED is linked to the degree of LDL oxidation and not LDL concentration itself [30]. Antioxidants may be protective against oxidative stress and preserve NO by

| Table 3 Effect of Placebo, *Phyllanthus emblica* 250 mg and *Phyllanthus emblica* 500 mg on biomarkers |
|---------------------------------------------------------------|
| Parameter | Placebo (A) (*n* = 18) | *Phyllanthus emblica* 250 mg (B) (*n* = 20) | *Phyllanthus emblica* 500 mg (C) (*n* = 21) |
| Baseline | 12 weeks | Mean % change | Baseline | 12 weeks | Mean % change | Baseline | 12 weeks | Mean % change |
| NO (µM/L) | 32.97 ± 4.02 | 32.58 ± 3.88 | −0.94% | 34.53 ± 5.81 | 47.88 ± 5.62 * | 41.89% | 32.62 ± 3.91 | 48.80 ± 5.97 * | 50.70% ** |
| GSH (µM/L) | 421.24 ± 61.1 | 429.3 ± 62.4 | 2.15% | 424.91 ± 103.16 | 524.91 ± 103.16 | 24.31% | 395.07 ± 58.03 | 599.33 ± 62.69 | 53.22% ** |
| MDA (nM/ml) | 3.79 ± 0.67 | 3.90 ± 0.60 | 3.53% | 3.86 ± 0.75 | 3.94 ± 0.60 | −21.02% | 3.85 ± 0.79 | 2.48 ± 0.38 * | −31.44% ** |
| hsCRP (mg/L) | 3.61 ± 0.74 | 3.66 ± 0.61 | 2.48% | 3.39 ± 0.74 | 3.06 ± 0.93 * | −39.68% | 3.51 ± 0.91 | 1.56 ± 0.63 * | −53.77% ** |

Values expressed as mean ± SD

| Table 4 Effect of Placebo, *Phyllanthus emblica* 250 mg and *Phyllanthus emblica* 500 mg on lipid profile |
|---------------------------------------------------------------|
| Parameter | Placebo (A) (*n* = 18) | *Phyllanthus emblica* 250 mg (B) (*n* = 20) | *Phyllanthus emblica* 500 mg (C) (*n* = 21) |
| Baseline | 12 weeks | Mean % change | Baseline | 12 weeks | Mean % change | Baseline | 12 weeks | Mean % change |
| TC (mg/dl) | 179.16 ± 18.2 | 184.16 ± 20.8 | 2.78% | 178.9 ± 21 | 165.7 ± 17.3 * | −7.17% | 183.48 ± 23.8 | 162.5 ± 18.9 | −11.11% ** |
| HDL-C (mg/dl) | 33.28 ± 2.74 | 33.29 ± 2.79 | 0.57% | 32.75 ± 2.34 | 35.10 ± 4.24 * | 7.33% | 31.57 ± 2.44 | 38.48 ± 3.28 * | 22.16% ** |
| LDL-C (mg/dl) | 136.7 ± 16.02 | 141.6 ± 14.79 | 3.83% | 133.2 ± 18.31 | 118.1 ± 17.9 * | −11.39% | 134.86 ± 12.24 | 105.52 ± 14.17 * | −21.80% ** |
| TG (mg/dl) | 184.3 ± 19.82 | 184.7 ± 21.62 | 0.18% | 184.4 ± 28.05 | 165.9 ± 23.43 * | −9.81% | 198.19 ± 31.84 | 157.24 ± 18.12 | −19.22% ** |

Values expressed as mean ± SD

*SD* Standard deviation, *TC* Total cholesterol, *HDL-C* High-density lipoprotein Cholesterol, *LDL-C* Low-density lipoprotein cholesterol, *TG* Triglycerides

* †* *p* < 0.01 compared to baseline value. ‡ *p* < 0.001 compared to placebo (A vs B, A vs C). § *p* < 0.001 B vs C. ‡ † *p* < 0.05 B vs C.
scavenging ROS and inhibiting oxidized LDL (OxLDL) formation [31]. Systemic inflammation biomarkers, hsCRP, is a predictor of CV events in healthy individuals as well as in persons with the MetS [32]. Antony et al. observed that treatment with Amlamax®, at doses of 500 mg/day and 1000 mg/day, brought about a significant fall in blood CRP levels [33]. Savita Khanna et al. demonstrated that treatment with standardized P. emblica fruit extract, 500 mg twice daily for 3 months, revealed a significant decrease in hsCRP (p < 0.001) in overweight /Class-1 obese adults [8]. In another study, it was observed that there was a significant change (~14.3%) in the level of hsCRP levels with Emblica officinalis treated group and a 7.4% increase with the placebo group [29]. We reported a similar reduction in hsCRP in our earlier study with P. emblica in T2DM patients [14]. Similar findings were reported in the present study in which 12-week treatment with PEE250 and PEE500 showed significant reduction in hsCRP compared to baseline and placebo.

Improvement in endothelial function and dyslipidaemia achieved by amla extract seems to be brought about by a number of factors, like preventing the initiation of early ED by its antioxidant action, preventing LDL oxidation, decreasing LDL cholesterol, besides inhibiting 3-hydroxy-3-methylglutaryl-Coenzyme A (HMG Co-A) reductase activity and elevating HDL-C level [34]. The antioxidant property and cholesterol-lowering activity of polyphenolic compounds present in amla seem to play a role here.

Conclusion
In the present study, standardized aqueous extract of Phyllanthus emblica significantly improved endothelial function, as evidenced by a significant decrease in reflection index, accompanied by a significant increase in NO, GSH and a significant decrease in MDA in subjects with MetS. In addition, the systemic inflammation biomarker, hsCRP, also decreased and the lipid profile improved significantly. Both 250 mg twice daily and 500 mg twice daily doses had significantly better effect than the placebo; however, the 500 mg twice daily dose was significantly more efficacious than the 250 mg twice daily dose. All the treatments were well tolerated. Hence we suggest that Phyllanthus emblica be used as an adjunct to conventional treatment (lifestyle modification and pharmacological intervention) in the management of MetS. Further studies in a larger population are warranted to address whether administration of Phyllanthus emblica may lead to a novel therapeutic alternative in improving the components of metabolic syndrome.

Abbreviations
ADR: Adverse drug reaction; ATP III: Adult Treatment Panel III; CRP: C-reactive protein; CV: Cardiovascular; CVD: Cardiovascular disease (CVD); DM: Diabetes mellitus; DPG: Digital volume plethysmography; DVP: Digital volume pulse; ED: Endothelial dysfunction; PEE: Phyllanthus emblica extract; FMD: Flow-mediated vasodilation; GSH: Glutathione; HDL –C: High-density lipoprotein cholesterol; hsCRP: High sensitivity C - reactive protein; LDL –C: Low-density lipoprotein cholesterol; LMwHTs: low molecular weight hydrolysable tannins; MDA: Malondialdehyde; MetS: Metabolic syndrome; NO: Nitric oxide; P. emblica: Phyllanthus emblica; RI: Reflection index; ROS: Reactive oxygen species; TG: Triglycerides

Acknowledgments
We are grateful to Dr.Y.S.N. Raju, Professor of General Medicine, NIMS, for his clinical support. The authors also acknowledge Natreon, Inc., USA, for providing study medications (Phyllanthus emblica capsules and Placebo capsules) and kits for biomarkers, Dr. I. Savanthi, an Ayurvedic physician for her expert advice and study coordinator Mr. Muralidhar.

Funding
We acknowledge Natreon, Inc., USA, for providing study medications and kits for biomarkers. The design of the study, collection, analysis, and interpretation of data and writing the manuscript was done by the investigators.

Availability of data and materials
The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
UP Protocol and study design, subject recruitment, follow-up of the subjects, interpretation of the data, drafting of the manuscript; approved the final version of the manuscript. PLM Subject recruitment, follow-up of the subjects, acquisition of the data, drafting of the manuscript, approved the final version of the manuscript. CN Subject recruitment, follow-up of the subjects, acquisition of the data, drafting of the manuscript, approved the final version of the manuscript.

Ethics approval and consent to participate
The present study was approved by Nizam’s Institute of Medical Sciences -Institutional Ethics Committee (NIEC), IRB/NIIMS/011(a) 2012. Written informed consent was taken from all the subjects prior to participation in the study.

Consent for publication
Not Applicable.

Competing interests
Authors declare no competing interests. We acknowledge Natreon, Inc., USA, for providing study medications and kits for biomarkers.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 11 December 2018 Accepted: 17 April 2019
Published online: 06 May 2019

References
1. Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National Heart, Lung, and Blood Institute; American Heart Association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009;120:1640–5.
2. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). Final Report. Circulation 2002; 106: 3143–3421.
3. The IDF consensus worldwide definition of the metabolic syndrome. International Diabetes Federation 2006. Available from https://www.idf.org/e-library/consensus-statements%20/60-idf%20consensus-worldwide-definitionofthe-metabolic-syndrome. [Accessed 17 May 2017].
4. Cozma A, Orasan O, Sampelean D, Fodor A, Vlad C, Negrean V, et al. Endothelial dysfunction in metabolic syndrome. Rom J Intern Med. 2009;47:133–40.
5. Van Guider GP, Hoetzer GL, Greiner JJ, Strauffer BL, DeSouza CA. Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity. 2006;14:2127–31.

6. Yubero-Serrano EM, Delgado-Lista J, Peruas-Ortuella P, Perez-Martinez P, Fuentes F, Marin C, et al. Oxidative stress is associated with the number of components of metabolic syndrome: LPGENE study. Exp Mol Med. 2013;45:626.

7. Sirikanthan K, Feyh A, Visheshwar H, Shapiro J, Soodi K. Systematic review of metabolic syndrome biomarkers: a panel for early detection, management, and risk stratification in the Western population. Int J Med Sci. 2016;13:25–38.

8. Khanna S, Das A, Speldener J, Rink C, Roy S. Supplementation of a standardized extract from Phyllanthus emblica improves cardiovascular risk factors and platelet aggregation in overweight/Class-1 obese adults. J Med Food. 2015;18:415–20.

9. Halcox JPJ, Ozkor MA, Mekonnen G, Quyyumi AA. Coronary endothelial dysfunction, obesity and metabolic syndrome. J Diabetes Metab. 2014;36:2.

10. Usharani P, Kishan PV, Fatima N, Kumar CU. A comparative study to evaluate the effect of highly standardized aqueous extracts of Emblica officinalis (Amla) as a target for prevention of cardiovascular disease. Diabetes Care. 2009;32(Suppl 2):S314–S21.

11. Bhandari PR, Kamdod MA. Emblica officinalis (Amla): a review of potential therapeutic applications. Int J Green Pharmacy. 2012;6:257–69.

12. Khan KH. Roles of Emblica officinalis in medicine. Bot Res Int. 2009;2:218–28.

13. Usha Rani P, Fatima N, Muralidhar N. Effects of Phyllanthus Emblica extract on endothelial dysfunction and biomarkers of oxidative stress in patients with type 2 diabetes mellitus: a randomised, double-blind, controlled study. Diabetes Metab Syndr Obes. 2013;6:275–84.

14. Usharani P, Kishan PV, Fatima N, Kumar CU. A comparative study to evaluate the effect of highly standardised aqueous extracts of Phyllanthus emblica, Vitamina somnilena and their combination on endothelial dysfunction and biomarkers in patients with type 2 diabetes mellitus. Int J Pharm Sci Res. 2014;5:2687–97.

15. Chowiwenzycz PJ, Kelly RP, MacCallum H, Millasseau SC, Andersson TL, Gosling RG, et al. Photoplethysmographic assessment of pulse wave reflection:blunted response to endothelium-dependent beta 2-adrenergic vasodilation in type II diabetes mellitus. J Am Coll Cardiol. 1999;34:2007–14.

16. Naidu MU, Sridhar Y, Usha Rani P, Mateen AA. Comparison of two β2 adrenoceptor agonists by different routes of administration to assess human endothelial function. Indian J Pharmacol. 2007;39:168–9.

17. Millasseau SC, Kelly RP, Ritter JM, Chowiwenzycz PJ. Determination of age related increases in large artery stiffness by digital pulse contour analysis. Clin Sci. 2002;103:371–7.

18. Vidyasagar J, Karunaka N, Reddy MS, Rajnarayan K, Surender T, Krishna DR. Oxidative stress and antioxidant status in acute organophosphorus insecticide poisoning. Indian J Pharmacol. 2004;36:76–9.

19. Katrina MM, Michael GE, David AW. A rapid, simple spectrophotometrically method for simultaneous detection of nitrate and nitrite. Biol Chem. 2001;5:62–71.

20. Elman GL. Tissue sulphydryl groups. Arch Biochem Biophys. 1959;82:70–7.

21. Kim HY, Okubo T, Juneja LR, Yokozawa T. The protective role of amla (Emblca officinalis Gaertn.) against fructose-induced metabolic syndrome in a rat model. Br J Nutr. 2010;103:502–12.

22. Gupta M, Mathur KC, Yadav K, Sharma P, Tilwani K, Narnolia PK, et al. Effect of Amla (Emblica officinalis) on markers of systemic inflammation and dyslipidemia. Indian J Clin Biochem. 2008;23:378–81.

23. Antony B, Merina B, Sheeba V, Mukkadan J. Effect of standardized Amla extracts on atherosclerosis and dyslipidemia. Indian J Pharm Sci. 2006;58:437–41.

24. Akhtar MS, Ramzan A, Ali A, Ahmad M. Effect of Amla fruit (Emblica officinalis Gaertn.) on blood glucose and lipid profile of normal subjects and type 2 diabetic patients. Int J Food Sci Nutr. 2011;62:609–16.

25. Biswas TK, Chakrabarti S, Pandit S, Jana U, Dey SK. Pilot study evaluating the use of Emblica officinalis standardized fruit extract in cardio-respiratory improvement and antioxidant status of volunteers with smoking history. J Herbal Med. 2014;188–94.

26. Anderson TJ. Assessment and treatment of endothelial dysfunction in humans. J Am Coll Cardiol. 1999;34:631–8.

27. Engler MM, Engler MB, Malloy MJ, Chiu EY, Schloletter MC, Paul SM, et al. Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia. Endothelial assessment of risk from lipids in youth (EARLY) trial. Circulation. 2003;108:1059–63.

28. Kamath DY, Xavier D, Sigamani A, Pais P. High sensitivity C-reactive protein (hsCRP) & cardiovascular disease: an Indian perspective. Indian J Med Res. 2015;142:261–8.

29. Antony B, Benny M, Kaimal TNB. A pilot clinical study to evaluate the effect of Emblica officinalis extract (amalax™) on markers of systemic inflammation and dyslipidemia. Indian J Clin Biochem. 2008;23:378–81.

30. Antony B, Merina B, Sheeba V, Mukkadan J. Effect of standardized Amla extracts on atherosclerosis and dyslipidemia. Indian J Pharm Sci. 2006;58:437–41.